JP2012116818A - Pharmaceutical composition for treatment of urinary system disease - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide a pharmaceutical composition for treating a urinary system that effectively controls infection and repeated seizures and promotes healing of a bladder surface wound.
A carbon material having a diameter of 2 nm to 2 mm is contained in an amount of 0.1 mg / ml to 100 mg / ml. The carbon material can be combined with metal granules containing at least one of silver, platinum, palladium, gold, zinc, and copper having a diameter of 2 nm to 2 mm. The carbon material combined with the metal granules is in contact with the bladder and related tissues to provide bactericidal performance and anti-inflammatory effects, and can effectively control infection and repeated seizures. It also has the effect of promoting the healing of wounds on the surface of the bladder and alleviating the pathological symptoms of cystitis patients. Furthermore, the urinary system is kept sterile by regular use, and the occurrence of bacterial urine, urinary tract infection, cystitis or nephritis can be suppressed.
[Selection] Figure 1

Description

  The present invention relates to a pharmaceutical composition that can be used medicinally and can be used for the treatment or prevention of diseases of the urinary system.

Conventionally, many urological diseases are cystitis or urinary tract infections in which the urinary tract is caused by bacteria, chemical drugs, radiation, anticancer drugs or exogenous infection. In some cases, drug administration reduces resistance, and bacteria can enter and cause infection. Urinary diseases are particularly prevalent in women and ureteral patients. The easiest way to determine whether cystitis is occurring is whether there is bacterial urine, that is, whether there are more than 10 ⁵ CFU / ml of urinary bacteria. If the amount of bacteria in the urine is too large, there may be cystitis or pyelonephritis. In the case of men, the ratio of bacteria at a position 2 cm away from the urethra is about 98%, and the ratio at a position 5 cm is 49%. In the case of women, the ratio is considered higher.

According to statistics from the 2007 Taiwan Intensive Care Unit, urinary tract infections occupy the top position with 37.5% of nosocomial infections, regardless of medical center or district hospital. In all ages, urinary tract infections are said to be the most common urinary tract disease caused by bacterial infections.
The main cause of extrinsic infection is invasive treatment such as ureteroplasty or cystoscopy often performed in hospitals. Invasive treatment brings bacteria into the bladder, causing ascending infection and further bacterial cystitis. In severe cases, acute cystitis or nephritis may occur.
Bacterial cystitis, which is commonly observed, causes a situation such as redness or swelling of the bladder mucosa, and blood vessel (Blood vessel, BV) hyperemia. On the other hand, interstitial cystitis causes inflammation between the submucosa and muscle layers. When cystitis occurs, discomfort and pain are generally felt in the bladder, and related medical conditions such as frequent urination and urgency occur. In particular, when cystitis treatment is inadequate, severe infection of the bladder may occur, causing the patient to lose kidney function, necessitating renal dialysis treatment, and not being associated with sepsis.

At present, the therapeutic methods used for cystitis are mainly pharmacotherapy, antibacterial bladder irrigation (Bladder irrigation), infusion (Infusion administration), and the like. However, in the single therapy of the injection method (Infusion administration), the combined therapy of the injection method and other therapies, or the sequential therapy combining the above three therapies, dimethyl sulfoxide, chlorpactin ( chlorpactin, heparin, hyaluronic acid (HA), adriamycin (ADM), chondroitin sulfate, sodium hydrogen carbonate, sulphonite, sodium nitrite (Pentosan Polysulfate Sodium), cromolyn sodium (c omolyn sodium), penicillin (Pencillin), using nitrofurazone, gentamycin (gentamicin) or mild silver protein (Mild Silver Protein) drugs such. Many of the above drugs have the effect of alleviating the symptoms of cystitis, such as pain, uric acid, and urgency, for the treatment of bladder mucosa and interstitial tissue layers.
Technologies for preventing bacterial infections of the urethra include antibiotic method prevention, urinary tract surface drug application technology, urinary tract technology plated with silver, and the like.

  However, in the above conventional cystitis treatment or urethral bacterial infection prevention technique, there are few cases where symptoms can be continuously alleviated or treated and used over a long period of time, and during the treatment period there is little Currently, side effects occur.

  As for the treatment of cystitis, the treatment that relies solely on the antibacterial drug cannot repair the bladder mucosa and stromal tissue immediately, but the actual effect cannot be achieved. If the damaged bladder mucosa and interstitial tissue are effectively repaired, and at the same time, the cause of the infection is found and the necessary treatment can be performed immediately, the infection can be effectively controlled and repeated seizures prevented. Can promote the healing of wounds on the bladder surface and relieve the patient's medical condition.

  The present invention has been made in the mirror of the above problems, and its purpose is to repair a broken bladder mucosa and interstitial tissue, and to suppress further bacterial invasion and reproduction, a urological disease It is providing the pharmaceutical composition which treats.

In order to solve the above problems, a pharmaceutical composition for treating the following urological diseases has been developed.
The pharmaceutical composition for treating a urological disease of the invention according to claim 1 is formed by combining a carbon material containing 60 mass% or more of carbon and a water-containing excipient, and can be used medicinally. Here, the diameter of the carbon material is 2 nm to 2 mm.
The carbon material is contained in an amount of 0.1 mg / ml to 100 mg / ml.
Further, the carbon material is bonded to metal granules containing at least one of silver, platinum, palladium, gold, zinc, and copper having a diameter of 2 nm to 2 mm. The carbon material combined with the metal granules can interact with the bladder and related tissues, for example, cystitis, acute cystitis, chronic cystitis, hemorrhagic cystitis, bacterial cystitis, emphysematous cystitis, It can treat and prevent interstitial cystitis, wounds on the bladder or urethra, and urinary tract infections. In addition, infection and recurrent seizures can be effectively suppressed, wound healing on the bladder surface can be promoted, and the patient's medical condition can be alleviated.

As a result, the pharmaceutical composition for treating a urinary system disease of the present invention, when cystitis occurs, quickly adsorbs bacteria that cause inflammation and eliminates the effect of endotoxin substances on the human body. It can then repair the destroyed bladder mucosa and interstitial tissue to prevent further bacterial entry and propagation. Therefore, effects such as healing of wounds on the surface of the bladder, control of infection, suppression of repeated seizures, and alleviation of cystitis pathology can be expected.
Therefore, the pharmaceutical composition for treating a urinary system disease of the present invention can prevent pathologic attacks of cystitis while effectively controlling infection, and promote the healing of bladder surface wounds, thereby reducing the pathological symptoms of cystitis patients. Can be relaxed.

It is a comparison figure of the inflammation inducer content in urine of each set rat of 1st Example of this invention, and bladder mass. It is a H & E dyeing | staining figure of the bladder of the normal rat of M1-1 (Normal) group of 1st Example of this invention. It is a bladder H & E staining figure after the inflammation induction by the inflammation inducer of the rat of M1-2 (LPS) group of 1st Example of this invention. FIG. 4 is an H & E staining diagram of the mucosal tissue of the bladder of the M1-2 (LPS) group in FIG. 3. H & E staining diagram of bladder in which M1-3 (LSP-ACF) group rats of the first embodiment of the present invention were infused with a pharmaceutical composition of a composite excipient after inducing inflammation with an inflammation-inducing agent It is. It is a comparison figure of the procalcitonin (Procalcitonin, PCT) density | concentration in the serum of each group rat of 1st Example of this invention, and a bladder mass. It is a H & E dyeing | staining figure of the bladder of the normal rat of M2-1 (Normal) group of 1st Example of this invention. It is a H & E dyeing | staining figure of the bladder in which inflammation was induced by the inflammation inducer of M2-2 (LPS) group of 1st Example of this invention. H & E staining diagram of bladder in which M2-3 (LPS-ACF) group rats of the first embodiment of the present invention were infused with a pharmaceutical composition of a composite excipient after inducing inflammation with an inflammation-inducing agent It is. It is a bladder H & E dyeing | staining figure of the normal rat of M3-1 (Normal) group of 2nd Example of this invention. FIG. 4 is an H & E staining diagram of the bladder after M3-2 (LPS) group rats of the second embodiment of the present invention were inflamed with an inflammation inducer. H & E staining diagram of bladder in which M4-3 (LPS-ACF) group rats of the second embodiment of the present invention were infused with a pharmaceutical composition of a composite excipient after inducing bladder inflammation with an inflammation inducer It is.

Hereinafter, embodiments of the present invention will be described in detail with reference to the drawings.
(First embodiment)
A pharmaceutical composition for treating urological diseases according to the first embodiment of the present invention is shown below.
In this example, the pharmaceutical composition for treating urological diseases is a pharmaceutically usable composite excipient formed by combining a carbon material containing 60% by mass or more of carbon and a water-containing excipient. .

The carbon material is granular, and includes carbon fiber, active carbon fiber, active carbon, graphite, expanded graphite, nano-carbon tube. ), Carbon nanocapsules, coke balls, and carbon black. The diameter is 20 nm to 2 mm, and the specific surface area (BET) is 20 m ² / g to 4000 m ² / g. In this embodiment, the carbon material is composed of activated carbon fiber powder containing 80% by mass or more of carbon, or activated carbon, and has a specific surface area (BET) value. It is preferable that it is 200 m < ² > / g-3000 m < ² > / g.

  On the other hand, the water-containing excipient contains at least one material of a buffer solution, an antibiotic (antibiotic agent), an antimicrobial agent, and a cystitis treatment drug (Treatment of interstitial cystis with drugs). The dosage is 0.01 mg / ml or more. In the present embodiment, the amount of the carbon material is preferably 0.1 mg / ml to 500 mg / ml.

(Second embodiment)
The main composition and effect of the second embodiment of the present invention are similar to those of the first embodiment, and therefore will not be described in detail.
The carbon material is further combined with small granular metal granules containing at least one of silver, platinum, palladium, gold, zinc and copper having a diameter of 2 nm to 2 mm. A metal granule is 20 mass% or less of the total mass of a carbon material and a metal granule. In 2nd Example, it is preferable that a small granule metal is 5 mass% or less of the total mass of a carbon material and a metal granule.
After the small granule metal is combined with the carbon material, it is further combined with a water-containing excipient to form a pharmaceutical composition capable of treating urinary diseases.

Antibiotics (antibiotic agents, antibiotics) used in water-containing excipients are trimethoprim-sulfame-thoxazole (TMP-SMX), trimethoprim (Trimethoprim MP). (Sulfame-thoxazole (SMX)), fluoroquinolones, ciprofloxacin, ofloxacin, cephalexin, and at least one tetracycline.
On the other hand, treatment agents for cystitis (Treatment of interstitial cystis drugs) used as hydrous excipients are dimethyl sulfoxide, hypochlorite (heparin), hyaluronic acid, hyaluronic acid. , HA), adriamycin (ADM), chondroitin sulfate, sodium bicarbonate, nitrite, pentosan polysulfide sodium, pentosan polysulfide sulfur , Bae It includes at least one of nicillin, nitrofurazone, gentamicin, and mild silver protein.

  Therefore, the carbon material of the pharmaceutical composition or the carbon material combined with the metal granule is brought into contact with the bladder and its related tissues, for example, cystitis, acute cystitis, chronic cystitis, hemorrhagic cystitis, bacteria Effective in the treatment and prevention of cystitis, emphysematous cystitis, interstitial cystitis, wounds in the bladder or urethra, or urinary tract infections. In addition, infection and repeated seizures can be effectively suppressed, healing of wounds on the surface of the bladder can be promoted, and the medical condition of the patient can be alleviated.

The structural features, operational techniques, and anticipatory effects of the above embodiment will be described as follows.
As shown in FIGS. 1 to 5, the carbon material of the pharmaceutical composition includes activated carbon fiber (50 μm to 100 μm) and a specific surface area (BET) of 200 m ² / g to 2000 m ^2. / G of granules.

In the first embodiment, a sterilized water buffer solution is used as a water-containing excipient. When the carbon material is added to a buffer solution and stirred sufficiently, a composite excipient containing the carbon material is produced. The dosage of the composite excipient is 0.2 mg / ml.
Three experimental Sprague-Dawley rats weighing about 290 g are used for the experimental body and divided into three groups.
(1), M1-1 (Normal): normal rat without injection of inflammation-inducing agent.
(2), M1-2 (LPS): Rats that were injected with an inflammation-inducing agent to induce bladder inflammation.
(3), M1-3 (LPS-ACF): Rats that were treated with injection with a complex vehicle after inducing inflammation.
Before starting the experiment, each rat is first anesthetized with urethane. After confirming that anesthesia is effective, the rat is fixed to a soft plate with a tape, and urethral intubation is performed with a polyethylene tube (PE-50).
After the above preparation is completed, the following experiment begins.

First, rats of the M1-2 (LPS) group and the M1-3 (LPS-ACF) group are respectively injected with protamine sulfate (PS) from the urethra into the bladder to damage the bladder mucosa. . Then, an inflammation inducer is injected. The inflammation-inducing agent to be injected in the above examples is a so-called endotoxin lipopolysaccharide (LPS) which has an effect of inducing bladder inflammation.
45 minutes after injecting protamine sulfate (PS), the bladder was washed by injecting normal saline to prevent damage to the bladder stromal layer (Lamina prolia, Lp) cells, Control the range of.

After bladder washing, an inflammation inducer, namely endotoxin 750 EU, is injected twice every 30 minutes to induce bladder inflammation. After 1 hour, the bladder is also washed with normal saline. After an additional hour after washing, the primary urine of 3 rats is collected.
Next, M1-3 (LPS-ACF) group of rats is injected with the pharmaceutical composition of the above-mentioned example having a dosage of 4 mg slash 20 ml. On the other hand, rats of the M1-2 (LPS) group are injected with only normal saline. The injection is performed once every 30 minutes, for a total of 4 injections. Three hours after the end of the injection, the secondary urine of three rats is collected.
Twenty-four hours after collecting the secondary urine, the bladders of 3 rats are collected, weighed, and H & E stained pathological sections of 3 sets of rat bladders are made.

As shown in FIG. 1, the analysis results of the primary collection urine are as follows.
Since the M1-1 (Normal) group is a control group, it is not necessary to collect them.
Inflammatory agent concentrations in rats of M1-2 (LPS) set reached 9.6 EU / ml, and M1-3 (LPS-ACF) set reached 36.0 EU / ml.
The analysis results of the second collection urine after 3 hours are as follows.
The concentration of inflammation inducer in the target group, M1-1 (Normal) group, is 1.0 EU / ml.
The inflammation-inducing agent concentration of the M1-2 (LPS) group was reduced to 1.8 EU / ml.
The inflammation-inducing agent content of the M1-3 (LPS-ACF) pair injected with the composite excipient pharmaceutical composition was reduced to 1.0 EU / ml.

When the results of the la inflammation inducer concentration test of the M1-1 (Normal) group, the M1-2 (LPS) group, and the M1-3 (LPS-ACF) group were compared, the following results were found.
In the M1-2 (LPS) group, the inflammation-inducing agent content in the primary urine is 9.6 EU / ml after injection of the inflammation-inducing agent, but the metabolism induces inflammation in the secondary urine 3 hours later by metabolism. The agent content was found to remain 1.8 EU / ml.
In contrast, in the M1-3 (LPS-ACF) group of rats, the concentration of inflammation-inducing agent in the primary urine reached 36.0 EU / ml, but the pharmaceutical composition of the composite excipient was injected. After that, the content of inflammation-inducing agent in the secondary urine decreased to 1.0 EU / ml, which is homologous to the control group M1-1 (Normal). Therefore, it was found that the pharmaceutical composition of the composite excipient has a therapeutic effect on the rat bladder already inflamed.

The therapeutic effect of the pharmaceutical composition of the composite excipient is also seen from the mass of the rat bladder.
The mass of the rat bladder of the M1-2 (LPS) set is 177.3 mg, while the mass of the rat bladder of the M1-3 (LPS-ACF) set injected with the pharmaceutical composition of the composite excipient is 134.8. Reduced to mg. This indicates that the pharmaceutical composition of the composite excipient has a therapeutic effect and has improved edema due to cystitis.

The internal situation of the rat bladder is shown in FIG.
FIG. 2 shows H & E staining of normal bladders from the M1-1 (Normal) set of rats, indicating that bladder mucosa epithelial cells (Epithelium, Ep) on the bladder surface are very smooth. The figure shows blood vessels (Blood Vessel, BV), epithelial cells (Epithelium, Ep), mucosal tissue (Muscle, M), connective tissue (Connective tissue, CT), and stromal layer (Lamina propria, Lp). appear.
FIG. 3 is an H & E staining diagram of the bladder after inflammation induction with an inflammation-inducing agent in rats of the M1-2 (LPS) group, and leukocytes gathered in the bladder interstitial layer (Lamina propria, Lp) below the mucosa due to inflammation Indicates that In the figure, white blood cells (WBC) gather on the surface of the inflamed bladder, and edema and bleeding are visible.
FIG. 4 shows that very severe internal bleeding has occurred in the internal tissue of the M1-2 (LPS) group of rats.

FIG. 5 is an H & E staining diagram of rat bladder of M1-3 (LPS-ACF) pair treated with a pharmaceutical composition of complex excipients. The bladder mucosa tissue was found to be very similar when compared to the normal rat bladder mucosa tissue of the M1-1 (Normal) set of FIG.
Serious inflammatory phenomena such as leukocyte aggregation, edema, and internal hemorrhage do not appear in rats of the M1-3 (LPS-ACF) group. This indicates that the pharmaceutical composition of the composite excipient has a therapeutic effect on rat bladder already inflamed.

The main implementation method of the embodiment shown in FIGS. 6 to 9 is similar to that of the first embodiment, and therefore will not be described in detail.
Since measurement of serum procalcitonin (PCT) concentration is a marker for determining severe bacterial infections such as bacterial infections showing a systemic inflammatory reaction, in this embodiment, procalcitonin (Procalcitonin) , PCT) concentration measurement.
Increasing procalcitonin (PCT) concentration indicates that the bladder inflammation phenomenon was caused by a bacterial infection, septic shock or other serious systemic bacterial infection.

According to FIG. 6, the M2-1 (Normal) group is a normal rat of the control group, and the concentration of procalcitonin (PCT) is 0.021 ng / ml.
The M2-2 (LPS) group was a rat in which inflammation was induced by an inflammation-inducing agent, and the concentration of procalcitonin (PCT) increased to 0.036 ng / ml.
The M2-3 (LPS-ACF) pair induces inflammation with an inflammation-inducing agent, and the rats treated with injection treatment have a procalcitonin (PCT) concentration of 0.02 ng / ml.
When the above results were compared, the concentrations of procalcitonin (PCT) in rats of the M2-3 (LPS-ACF) group and M2-1 (Normal) matched. Compared to 177.6 mg of the bladder mass of the M2-2 (LPS) group of rats, the bladder mass of the M2-3 (LPS-ACF) group of rats decreased to 138.1 mg. This indicates that the pharmaceutical composition of the composite excipient has a certain therapeutic effect on bladder inflammation.

7-9 are H & E staining diagrams of each set of rat bladder.
In the rat bladder tissue section of the M2-1 (Normal) group shown in FIG. 7, a very smooth bladder mucosa is visible.
In the rat bladder tissue section of the M2-2 (LPS) group shown in FIG. 8, a serious edema phenomenon is seen on the left side in the figure.
In the rat bladder tissue section of the M2-3 (LPS-ACF) group shown in FIG. 9, a smooth bladder mucosa surface appears, and no bladder inflammation phenomenon such as leukocyte aggregation, edema, or internal bleeding appears.
Thus, it can be seen that the pharmaceutical composition of the composite excipient has a therapeutic effect on rat bladder already inflamed.

10-12 are H & E stained pathological tissue sections of each set of rat bladder. Since the main implementation method is the same as that of the first embodiment, it will not be described in detail. The M3-3 (LPS-ACF) group is a second embodiment of the present invention. The pharmaceutical composition used in the examples is for treating cystitis, which is formed by combining nano-level metal granules and a carbon material and combining with a water-containing excipient.
FIG. 10 shows no pathological conditions such as inflammation, edema, and internal bleeding in bladder H & E stained sections of normal rats of the M3-1 (Normal) group.

As shown in FIG. 11, inflammation in the rat bladder of the M3-2 (LPS) group is induced by inflammation-inducing agents, and serious inflammatory phenomena such as leukocyte aggregation, edema, and internal bleeding appear.
In addition, as shown in FIG. 12, the rats of the M4-3 (LPS-ACF) group were treated with a carbon material combined with metal granules containing silver after inducing inflammation with an inflammation-inducing agent, so that leukocyte aggregation, edema, internal bleeding Inflammation such as this does not appear.
Therefore, it is clear that the pharmaceutical composition formed by combining the carbon material and the metal granule containing silver has the effect of sterilizing and alleviating the symptoms of cystitis.

From the above description, the advantages and expected effects of the above embodiment are as follows.
1. The above example is a pharmaceutical composition for treating a urological disease as a pharmaceutically usable composite excipient formed by combining a carbon material and a water-containing excipient. And it can cope with disease of bladder mucosa (bladder mucosa) and has a long-term therapeutic effect while alleviating the pathology of cystitis.
2. The above example is a pharmaceutical composition for treating urological diseases as a pharmaceutically usable composite excipient formed by combining a carbon material with a water-containing excipient. And it has a repair action with respect to bladder mucosa (bladder mucosa), and can anticipate the further therapeutic effect.
3. The pharmaceutical composition for treating the urinary system of the above example is a nano-level metal containing at least one of silver, platinum, palladium, gold, zinc, and copper whose carbon material has a diameter of 2 nm to 2 mm. It binds to the granules and can enhance the effect of alleviating the symptoms of sterilization and cystitis.
4. The pharmaceutical composition for treating urological diseases of the above examples, because the carbon material has a relatively high specific surface area (BET) and good biocompatibility, adsorb bacteria themselves, Rapidly reduce the amount of bacteria in the bladder to below 10 ⁵ CFU. In addition, by adsorbing harmful substances such as bacterial exotoxin and endotoxin (LPS) and excreting them together with urine, the inflammation reaction of cystitis can be reduced and the effect of prevention can be achieved.

  The present invention described above is not limited to the above-described embodiments, and can be applied to various embodiments without departing from the gist thereof.

  While the present invention has novelty that is a requirement of patents, the present invention has sufficient inventive step as compared with conventional similar products. It is also highly practical and meets social needs. Furthermore, the industrial utility value is considered extremely high.

Claims (20)

A carbon material having a diameter of 2 nm to 2 mm and containing 60% by mass or more of carbon,
A hydrous excipient, and
A pharmaceutical composition for treating a urological disease, which is medicinally acceptable and is characterized by alleviating symptoms of cystitis by contact with the bladder and related tissues.   The pharmaceutical composition for treating a urological disease according to claim 1, wherein the carbon material is contained in an amount of 0.01 mg / ml or more.   The pharmaceutical composition for treating urological diseases according to claim 2, wherein the carbon material is contained in an amount of 0.1 mg / ml to 500 mg / ml.   The pharmaceutical composition for treating a urological disease according to claim 1, wherein the carbon material contains 80% by mass of carbon. The carbon material is bonded with metal granules containing at least one of silver, platinum, palladium, gold, zinc, and copper having a diameter of 2 nm to 2 mm,
The pharmaceutical composition for treating a urological disease according to claim 1, wherein the metal granule accounts for 20 mass% or less of the total mass of the carbon material and the metal granule.   The pharmaceutical composition for treating a urological disease according to claim 5, wherein the metal granule occupies 5 mass% or less of the total mass of the carbon material and the metal granule.   The carbon material includes at least one of carbon fiber, activated carbon fiber, activated carbon, graphite, expanded graphite, nanocarbon tube, carbon nanocapsule, coke ball, and carbon black. A pharmaceutical composition for treating urological diseases.   The pharmaceutical composition for treating urological diseases according to claim 1, wherein the carbon material has a diameter of 20 nm to 2 mm and a carbon layer planar deposition thickness of 1 nm to 1000 mm.   The pharmaceutical composition for treating a urological disease according to claim 1, wherein the water-containing excipient contains at least one of a buffer, an antibiotic, and a cystitis therapeutic drug.   10. The antibiotic includes at least one of trimethoprim sulfamethoxazole, trimethoprim, sulfamethoxazole, fluoroquinolone, ciprofloxacin, ofloxacin, cephalexin, and tetracycline. A pharmaceutical composition for treating a urinary system disease described in 1.   The bladder drug is dimethylsulfoxide), hypochlorous acid, heparin, hyaluronic acid, adriamycin, chondroitin sulfate, sodium bicarbonate, nitrous acid, pentosan polysulfate sodium, cromolyn sodium, penicillin, nitrofurazone, gentamicin, and The pharmaceutical composition for treating a urinary system disease according to claim 9, which is a therapeutic agent for cystitis comprising at least one of mild silver proteins. Pharmaceutical composition for the treatment of urinary system diseases according to claim 1 specific surface area value, which is a ^{20 m 2 / g ~ 4000 m} 2 / g of the carbon material. The pharmaceutical composition for treating urological diseases according to claim 12, wherein the carbon material has a specific surface area value of 200 m ² / g to 2000 m ² / g. A carbon material containing 60 mass% or more of carbon,
A hydrous excipient, and
The carbon material has a diameter of 2 nm to 2 mm and is bonded to a metal granule of 20% by mass or less, and includes carbon fiber, activated carbon fiber, activated carbon, graphite, expanded graphite, nanocarbon tube, carbon nanocapsule, and coke ball. And including at least one of carbon black,
A pharmaceutical composition for treating a urinary disease, which is medicinally acceptable and is characterized by sterilization and relieving symptoms of cystitis by mutual contact with the bladder and related tissues. The carbon material contains 80% by mass or more of carbon, and combines with a small granule metal containing at least one of silver, platinum, palladium, gold, zinc, and copper having a diameter of 5 nm to 2 mm.
The pharmaceutical composition for treating urological diseases according to claim 14, wherein the metal granule occupies 5 mass% or less of the total mass of the carbon material and the metal granule.   The pharmaceutical composition for treating urological diseases according to claim 14, wherein the carbon material is contained in an amount of 0.1 mg / ml to 500 mg / ml. The specific surface area of the carbon ^{material, 200 m 2 / g ~2000 m} 2 / g pharmaceutical composition for the treatment of urinary system diseases according to claim 14, characterized in that a.   The pharmaceutical composition for treating a urological disease according to claim 14, wherein the water-containing excipient contains at least one of a buffer, an antibiotic, and a cystitis therapeutic agent.   The antibiotic includes at least one of trimethoprim sulfamethoxazole, trimethoprim, sulfamethoxazole, fluoroquinolone, ciprofloxacin, ofloxacin, cephalexin, and tetracycline. A pharmaceutical composition for treating a urinary system disease described in 1.   The bladder therapeutic agent is dimethylsulfoxide, hypochlorous acid, heparin, hyaluronic acid, adriamycin, chondroitin sulfate, sodium bicarbonate, nitrous acid, pentosan polysulfate sodium, cromolyn sodium, penicillin, nitrofurazone, gentamicin, and The pharmaceutical composition for treating a urological disease according to claim 18, comprising at least one of mild silver protein.